End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
53.67 CNY | +4.48% |
|
+13.83% | +1.36% |
Jun. 03 | Novary CFO Resigns | MT |
Apr. 25 | Novoray Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- With an expected P/E ratio at 41.77 and 30.54 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.36% | 1.32B | - | ||
+1.91% | 104B | A- | ||
-7.19% | 62.15B | A- | ||
+84.76% | 50.92B | B | ||
+6.22% | 36.09B | B | ||
+0.60% | 30.95B | A- | ||
+4.57% | 18.85B | B- | ||
+18.55% | 17.61B | C+ | ||
+8.96% | 13.97B | B- | ||
+76.66% | 13B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688300 Stock
- Ratings Novoray Corporation